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Background: Antiphospholipid antibody syndrome is characterized by venous and/or arterial thrombosis, and is
found in patients with systemic lupus erythematosus. Its diagnosis requires the presence of both clinical and
laboratory findings, such as positive anti-cardiolipin and anti-β2 glycoprotein I antibodies and lupus anticoagulant.
However, cardiolipin is a minor component of the vascular endothelial cells in human, and phosphatidylcholine and
phosphatidylethanolamine are major components.
Case presentation: A 15-year-old female suddenly developed massive left intraretinal hemorrhaging due to central
retinal vein occlusion. She also had a butterfly rash, and her laboratory findings revealed positive serum anti-nuclear
antibodies and decreased serum complement. During this episode, she was diagnosed with systemic lupus
erythematosus. Although she was negative for serum anti-cardiolipin IgG and anti-β2 glycoprotein I antibodies as well
as lupus anticoagulant, her serum anti-phosphatidylcholine, anti-phosphatidylethanolamine, anti-phosphatidylinositol
and phosphatidylserine IgG antibodies levels were increased.
Conclusion: Pediatric cases of central retinal vein occlusion are rare. Even in patients without anti-cardiolipin or
anti-β2 glycoprotein I antibodies and lupus anticoagulant, there is the potential for the development of
antiphospholipid antibody-related thrombosis.
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Anti-phosphatidylcholine antibodyBackground
Antiphospholipid antibody syndrome (APS) is character-
ized by venous and/or arterial thrombosis and recurrent
fetal loss, and is found in patients with systemic lupus ery-
thematosus (SLE) [1]. A diagnosis of APS requires the
presence of both clinical and laboratory findings, such as
positive anti-cardiolipin (CL) and anti-β2 glycoprotein I
antibodies and lupus anticoagulant. However, CL is a
minor component of phospholipids in humans [2].* Correspondence: kseigo@oita-u.ac.jp
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article, unless otherwise stated.This report describes central retinal vein occlusion
(CRVO) in a pediatric patient with SLE and anti-
phospholipids antibodies without anti-CL antibody.Case presentation
A female patient was born without any perinatal problems
and her psychomotor and growth development had been
normal. Her father had Crohn’s disease and her elder
brother had atopic dermatitis. She developed allergic con-
junctivitis when she was around 10 years old and was ad-
ministered betamethasone eye-drops. She also developed a
butterfly rash and photosensitivity at the age of 14. And
then, she suddenly developed a left visual disturbance
without any premonitory sign at the age of 15. Her visual
acuity (left: 0.04, right: 1.2) showed asymmetry. Her eyetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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orrhaging due to CRVO (Figure 1). Her blood pressure
was 100/70 mmHg and she had not history of any cardio-
vascular disorders or diabetes.
Her laboratory findings showed pancytopenia with a
WBC count of 4,680/mm3, RBC count of 351 × 104/mm3,
Hb level of 9.9 g/dl, Ht level of 30.3% and PLT count of
16.1 × 104/mm3, an increased erythrocyte sedimentation
rate of 54 mm/hr (<10), but APTT of 28.0 seconds was
within the normal range. There was increased anti-nuclear
antibody titer of x640 (<x40), ds-DNA antibody titer of
377.7 IU/ml (<12.0) and ss-DNA antibody titer of
722.4 AU/ml (<25.0) and a decline in complement
levels of C3 14 mg/dl (86–160), C4 3 mg/dl (17–45)
and CH50 < 10 U/ml (23–46). However, both her anti-
CL IgG antibody of 9 U/ml (<10; EIA method), anti-β2
glycoprotein I antibody of 1.3 U/ml (<3.5; EIA method)
and lupus anticoagulant of 1.2 (<1.4; Dilute Russell’s
Viper Venom Time) were within the normal range.
Intravenous low-molecular weight heparin of reviparin
was initiated, and she received steroid pulse therapy, oral
fexofenadine and levocabastine eye-drops. The intraret-
inal hemorrhaging gradually improved, and the patient
was treated with warfarin, aspirin, prednisolone and ta-
crolimus. Her anti-CL IgG antibody titer was examined
four times every two weeks, however, all of evaluations
showed negative results (2/3/1/1 U/ml). The second
examination of the anti-β2 glycoprotein I antibody titer
also showed a level less than 1.3 U/ml.
After informed consent was provided by the patient
and parents, we examined the patient for other antipho-
spholipid antibodies according to the Guidelines of the
European Consensus described the development of the
antiphospholipid IgG antibody ELISA assay, as described
previously [3]. Briefly, 1 ml of whole blood was drawn
twice at an interval of 12 weeks. Microtitre plates were
coated with 50 μg/ml phosphatidylcholine (PC, Nacalai
tesque, Kyoto, Japan), phosphatidylethanolamine (PE,
Sigma, St. Louis, USA), phosphatidylinositol (PI, NacalaiFigure 1 Finding of eye fundus. A 15-year-old female patient showed mtesque, Kyoto, Japan) and phosphatidylserine (PS,
ChromaDex, Inc, California, USA) and were incubated
overnight. On the following day the plates were incubated
with triplicate serum at a 1/10 dilution for one hour.
After wash, the plates were incubated with goat anti-
human IgG (Santa Cruz Biotechnology, Inc, California,
USA) at a 1/2,000 dilution for one hour. Using substrate
of o-phenylenediamine (Sigma, St. Louis, USA), the ab-
sorbance was read at 450 nm with ELISA reader. Age-
matched three patients with APS with anti-CL IgG
antibody, four patients with SLE and eight patients
with non-collagen disease controls were also enrolled
as disease controls. The positive cut-off value was de-
fined as two standard deviations above the mean in the
controls subjects. Since there were no positive control
antiphospholipid antibodies, we calculated the optical
density (OD) according to the method used in previous
reports [3].
Her anti-PC IgG antibody (0.342 OD), anti-PE IgG
antibody (0.190 OD), anti-PI IgG antibody (0.290 OD),
and anti-PS IgG antibody (0.214 OD) were increased
in comparison to not only normal controls (anti-PC;
0.095 ± 0.009 OD, anti-PE; 0.079 ± 0.019 OD, anti-PI;
0.082 ± 0.012 OD, anti-PS; 0.084 ± 0.033 OD) but also
other patients with APS (anti-PC; 0.181 ± 0.076 OD,
anti-PE; 0.117 ± 0.021 OD, anti-PI; 0.130 ± 0.039 OD,
anti-PS; 0.129 ± 0.094 OD) and SLE (anti-PC; 0.117 ±
0.019 OD, anti-PE; 0.110 ± 0.038 OD), anti-PI; 0.097 ±
0.046 OD, anti-PS; 0.090 ± 0.037 OD). The elevation
of anti-PC (0.202 OD), anti-PE (0.114 OD), anti-PI
(0.181 OD), and anti-PS (0.139 OD) IgG antibodies
persisted after 12 weeks.
Conclusion
CRVO in pediatric patients is rare and has been de-
scribed to be caused by cardio-vascular disorders, such
as hypertension, heart failure, diabetes, atherosclerosis
and APS [4]. APS may be considered present in a patient
with thrombotic events and positive antiphospholipidassive left intraretinal hemorrhaging.
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antibodies and lupus anti-coagulant titer that is verified
on at least two occasions at least 12 weeks apart [1].
However, CL is a minor component of phospholipids
in humans and anti-CL antibodies have cross-reactivity
with other major components of phospholipids. Takamura
et al. [2] described that even in both arterial and venous
endothelial cells, PC (49.0 ± 0.1/50.5 ± 0.1%) and PE
(28.1 ± 0.3/25.5 ± 0.4%) are more extensively distributed
than CL (2.0 ± 0.1/2.3 ± 0.2%). Reshetniak et al. [5] found
that only 40% of patients with SLE had anti-CL antibody
but 60% had anti-PC antibody. Kalashnikova et al. [6]
described that anti-PE antibody was present in 46% of
anti-CL and lupus anticoagulant-negative patients.
Von Schieven et al. [7] found no significant difference
in the prevalence of anti- anti-β2 glycoprotein I between
SLE children with or without thrombosis. Berard et al.
[8] reported that 15 patients with anti-PE antibodies
without anti-CL antibodies developed thromboembolic
episodes. Bertolaccini ML et al. [9] also showed that anti-
PS/prothrombin antibodies also act as risk factor for
thrombosis. Moreover, Kuksis et al. [10] described that
decreased plasma levels of the PC is an indicator of
atherosclerosis. These previous reports indicated that
anti-PC, −PE, and -PS increases the risk of thrombosis
and atherosclerosis even in patients without anti-CL
antibody.
The examination of patients for anti-CL and anti-β2
glycoprotein I antibodies and lupus anticoagulant is insuf-
ficient to understand the essential pathology of antipho-
spholipid antibody-related thrombosis. Even in patients
without anti-CL and anti-β2 glycoprotein I antibodies or
lupus anticoagulant, there is the potential for the develop-
ment of antiphospholipid antibody-related thrombosis.
Consent
Informed consent was obtained from the patient and her
parents for publication of this case report. A copy of the
consent form is available for review from the Editor of
this journal.
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